Apnimed (NASDAQ:APMD – Get Free Report) released its quarterly earnings data on Monday. The company reported ($1.05) earnings per share for the quarter, FiscalAI reports. The business had revenue of $2.48 million for the quarter.
Apnimed Stock Performance
Shares of NASDAQ APMD opened at $16.92 on Monday. The company’s 50-day moving average is $20.52. The stock has a market cap of $704.40 million and a P/E ratio of 6.43. Apnimed has a 52-week low of $13.88 and a 52-week high of $35.29.
Wall Street Analysts Forecast Growth
APMD has been the topic of several analyst reports. Lifesci Capital began coverage on shares of Apnimed in a research note on Tuesday, August 25th. They issued an “outperform” rating and a $50.00 target price on the stock. Evercore began coverage on shares of Apnimed in a research report on Tuesday, August 25th. They set an “outperform” rating for the company. Wall Street Zen upgraded shares of Apnimed to a “hold” rating in a report on Saturday, August 8th. Zacks Research raised Apnimed to a “hold” rating in a research report on Wednesday, August 26th. Finally, Weiss Ratings assumed coverage on Apnimed in a research note on Tuesday, October 27th. They set a “sell (e-)” rating on the stock. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.33.
Check Out Our Latest Research Report on Apnimed
Apnimed Company Profile
Apnimed is a clinical-stage pharmaceutical company focused on developing medicines for sleep-related breathing disorders, particularly obstructive sleep apnea. The company aims to offer drug-based treatment options for people who may not use or benefit from existing device-based therapies. Its lead candidate, AD109, is an investigational oral combination of atomoxetine and aroxybutynin (oxybutynin) designed to help maintain upper-airway muscle activity during sleep. Apnimed has evaluated AD109 in clinical trials for obstructive sleep apnea; it is not an approved treatment.
Featured Stories
- Five stocks we like better than Apnimed
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Apnimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apnimed and related companies with MarketBeat.com's FREE daily email newsletter.
